Review of real-world studies on capmatinib use in MET-mutated lung cancer
https://doi.org/10.37489/2782-3784-myrwd-064
EDN: LWCLXM
Abstract
Lung cancer occupies a leading position in the structure of mortality from malignant neoplasms, so in 2022, mortality from lung cancer was 31.66 per 100,000 population, in 2022, 44,981 patients were registered with a diagnosis of lung cancer for the first time in their life, the one-year mortality rate is 44.8 %. One of the genes involved in the development of lung cancer tumor cells is the MET gene, in which several different mutations have been found, but the deletion of exon 14 is the most common. This mutation occurs in 3–4 % of cases of non-small-cell lung cancer (NSCLC), is an independent factor in poor prognosis, and is associated with short overall survival. The drug capmatinib was first registered in 2020 specifically for treating NSCLC in the presence of a deletion of exon 14 in the MET gene. This study systematically reviewed the real-world clinical practice studies of capmatinib in NSCLC.
About the Authors
A. A. Kurylev
First St. Petersburg State Medical University named after I. P. Pavlov
Russian Federation
Competing Interests:
Russian Federation
Alexey A. Kurylev — Cand. Sci. (Med.), associate professor Department of Clinical Pharmacology and Evidence-Based Medicine
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
A. S. Kolbin
First St. Petersburg State Medical University named after I. P. Pavlov; St. Petersburg State University,
Russian Federation
Competing Interests:
Russian Federation
Alexey S. Kolbin — Dr. Sci. (Med.), Professor, Head. Department of Clinical Pharmacology and Evidence-Based Medicine; Professor of the Department of Pharmacology, Faculty of Medicine
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
I. R. Svechkareva
First St. Petersburg State Medical University named after I. P. Pavlov
Russian Federation
Competing Interests:
Russian Federation
Izabella R. Svechkareva — resident of the department of Clinical Pharmacology and Evidence-Based Medicine
St. Petersburg
Competing Interests:
The authors declare no conflict of interest.
References
1. Clinical guidelines of the Ministry of Health of Russia. Malignant neoplasms of the bronchi and lungs.
2. Malignant neoplasms in Russia in 2022 (morbidity and mortality) / edited by A.D. Kaprin et al.] – M.: P.A. Herzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, 2023. – ill. – 275 p.
3. The state of oncological care for the population of Russia in 2022. Edited by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow Oncology Research Institute – branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, 2022. – ill. – 239 p.
4. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer. Version 5.2024 – April 23, 2024. Электронный ресурс. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
5. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer. 2018 Sep;123:76-82. doi: 10.1016/j.lungcan.2018.07.006. Epub 2018 Jul 6. PMID: 30089599.
6. Huang C, Zou Q, Liu H, Qiu B, Li Q, Lin Y, Liang Y. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations. Curr Treat Options Oncol. 2020 Apr 18;21(4):33. doi: 10.1007/s11864-020-0723-5.
7. Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumours – molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. doi: 10.1038/s41571-020-0377-z.
8. Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, Li H, Pan Y, Chak WP, Ng CS, Mok TS, To KF. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin Cancer Res. 2016 Jun 15;22(12): 3048-56. doi: 10.1158/1078-0432.CCR-15-2061.
9. Yeung SF, Tong JHM, Law PPW, Chung LY, Lung RWM, Tong CYK, Chow C, Chan AWH, Wan IYP, Mok TSK, To KF. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. J Thorac Oncol. 2015 Sep;10(9):1292-1300. doi: 10.1097/JTO.0000000000000620.
10. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600.
11. Hong L, Zhang J, Heymach JV, Le X. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Ther Adv Med Oncol. 2021 Feb 15;13:1758835921992976. doi: 10.1177/1758835921992976.
12. Vuong HG, Ho ATN, Altibi AMA, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer. 2018 Sep;123:76-82. doi: 10.1016/j.lungcan.2018.07.006.
13. Illini O, Fabikan H, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Pall G, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, Weinlinger C, Valipour A, Hochmair MJ. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol. 2022 Jun 13;14:17588359221103206. doi: 10.1177/17588359221103206.
14. Asad Zadeh Vosta Kolaei F, Cai B, Kanakamedala H, Kim J, Doban V, Zhang S, Shi M. Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations: A Descriptive Analysis From the US. Front Oncol. 2022 Feb 25;12:786124. doi: 10.3389/fonc.2022.786124.
15. Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024;20(22):1553-1563. doi:10.2217/fon-2023-1064.
16. Wolf J, Souquet PJ, Goto K, et al. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clinical Lung Cancer. 2023 Nov; 24(7):641-650.e2. DOI: 10.1016/j.cllc.2023.08.011.
17. Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Ansquer VD, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain meta-stases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-228. doi: 10.2217/fon-2022-1133.
18. Wolf J, et al. 1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients. Annals of oncology. Volume 31, S863, DOI: 10.1016/j.annonc.2020.08.1660.
19. Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho A, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NS-CLC: Results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030.
20. Babey H, Jamme P, Curcio H, Assié JB, Veillon R, Doubre H, Pérol M, Guisier F, Huchot E, Decroisette C, Falchero L, Corre R, Cortot A, Chouaïd C, Descourt R. Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Target Oncol. 2023 Jul;18(4):585-591. doi: 10.1007/s11523-023-00976-4.
21. Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJ-Moa2002787.
22. Fraser M, Seetharamu N, Diamond M, Lee CS. Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives. Cancer Manag Res. 2023 Nov 3;15:1233-1243. doi: 10.2147/CMAR.S386799.
Review
For citations:
Kurylev A.A., Kolbin A.S., Svechkareva I.R. Review of real-world studies on capmatinib use in MET-mutated lung cancer. Real-World Data & Evidence. 2025;5(1):3-12. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-064. EDN: LWCLXM
Views:
266
Email this article 
Post a Comment 